# Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer

> **NCT06765590** · NA · RECRUITING · sponsor: **Sichuan Huiyu Pharmaceutical Co., Ltd** · enrollment: 24 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** T, 260 mg/m2, paclitaxel for injection (albumin-bound)
- **DRUG:** R, 260 mg/m2, paclitaxel for injection (albumin bound).

## Key facts

- **NCT ID:** NCT06765590
- **Lead sponsor:** Sichuan Huiyu Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-12
- **Primary completion:** 2026-06-12
- **Final completion:** 2026-10-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06765590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06765590, "Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06765590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*